Compass Therapeutics’ (CMPX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the stock.

Separately, Wedbush reissued an outperform rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Friday, March 22nd.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $1.57 on Tuesday. The stock has a 50 day moving average price of $1.84 and a 200 day moving average price of $1.73. Compass Therapeutics has a 52 week low of $1.15 and a 52 week high of $3.62. The stock has a market capitalization of $216.02 million, a PE ratio of -4.62 and a beta of 0.78.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). As a group, research analysts forecast that Compass Therapeutics will post -0.48 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently made changes to their positions in CMPX. BlackRock Inc. lifted its position in shares of Compass Therapeutics by 291.5% in the second quarter. BlackRock Inc. now owns 6,032,292 shares of the company’s stock valued at $19,183,000 after buying an additional 4,491,397 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $4,414,000. Braidwell LP lifted its position in shares of Compass Therapeutics by 79.0% in the first quarter. Braidwell LP now owns 3,247,847 shares of the company’s stock valued at $10,620,000 after buying an additional 1,433,581 shares during the last quarter. State Street Corp lifted its position in shares of Compass Therapeutics by 334.1% in the second quarter. State Street Corp now owns 1,746,514 shares of the company’s stock valued at $5,554,000 after buying an additional 1,344,201 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Compass Therapeutics by 104.6% in the second quarter. Geode Capital Management LLC now owns 1,808,207 shares of the company’s stock valued at $5,750,000 after buying an additional 924,644 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.